A direct in vivo measurement of 99mtc‐methylene diphosphonate protein binding

Nuclear Medicine Communications

Volumn 24, Issue 7, 2003, Pages 829-835

  Blake, G M ^a   Moore, A E B ^a   Park holohan S J ^a   Fogelman, I ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

99mTc methylene diphosphonate,; Bone plasma clearance; Cr EDTA; Glomerular filtration rate; Protein binding

Indexed keywords

CHROMIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; EDETIC ACID; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM TC 99M HYDROXYMETHYLENE DIPHOSPHONATE;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; PROTEIN BINDING; RADIOISOTOPE DIAGNOSIS; SCINTISCANNING;

AGED; CHROMIUM RADIOISOTOPES; DIAGNOSTIC TECHNIQUES, RADIOISOTOPE; EDETIC ACID; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; METABOLIC CLEARANCE RATE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROTEIN BINDING; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE;

EID: 2142687652     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200307000-00014     Document Type: Article

References (30)

1. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene disphosphonate - a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med 1975; 16: 744-755.
2. 18F-fluoride for bone imaging. Semin Nucl Med 1972; 2: 31-37.
3. 99mTc-methylene diphosphonate. Semin Nucl Med 2001; 31: 28-49.
4. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc-99m disphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978; 19: 270-275.
5. Hyldstrup L, Mogensen N, Jensen GF, et al. Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism. Scand J Clin Lab Invest 1984; 44: 105-109.
6. Thomsen K, Nilas L, Mogensen T, et al. Determination of bone turnover by urinary excretion of 99m-Tc-MDP. Eur J Nucl Med 1986; 12: 342-345.
7. 18F]fluoride kinetics in humans. J Nucl Med 1978; 19: 1301-1309.
8. Todd Makler P, Charkes ND. Studies of skeletal tracer kinetics IV. Optimum time delay for Tc-99m(Sn) methylene disphosphonate bone imaging. J Nucl Med 1980; 21: 641-645.
9. Charkes ND, Seigel JA. An analytical solution set for a fourcompartment mixed mammillary/catenary model. Nucl Med Commun 1999; 20: 575-580.
10. 99mTc-methylene diphosphonate. J Nucl Med 2002; 43: 338-345.
11. D'Addabbo A, Rubini G, Mele M, et al. A new method of assessing Tc-99m-MDP bone uptake from a bone scan image: quantitative measurement of radioactivity in global skeletal region of interest. Nucl Med Commun 1992; 13: 55-60.
12. Brenner W, Bohuslavizki KH, Sieweke N, et al. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med 1997; 24: 1284-1290.
13. Carnevale V, Frusciante V, Scillitani A, et al. Age-related changes in the global skeletal uptake of technetium-99m methylene disphosphonate in healthy women. Eur J Nucl Med 1996; 23: 1473-1477.
14. 99mTctechnetium methylene disphosphonate with age: relevance to the pathogenesis of bone loss. J Nucl Med 2000; 41: 1478-1483.
15. 99mTc-methylene disphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporosis Int 2002; 13: 829-834.
16. Hawkins RA, Choi Y, Huang S-C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992; 33: 633-642.
17. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med 1997; 38: 1970-1976.
18. 18F-fluoride positron emission tomography in postmenopausal women. J Bone Miner Res 2000; 15: 763-769.
19. 18F-fluoride positron emission tomography. J Bone Miner Res 2002; 17: 854-859.
20. Chen PS, Smith FA, Gardiner DE, et al. Renal clearance of fluoride. Proc Soc Exp Biol Med 1956; 92: 879-883.
21. Carlson CH, Armstrong WD, Singer L. Distribution, migration and binding of whole blood fluoride evaluated with radiofluoride. Am J Physiol 1960; 199: 187-189.
22. Taves DR. Electrophoretic mobility of serum fluoride. Nature 1968; 220: 582-583.
23. Hyldstrup L, McNair P, Ring P. Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h. Eur J Nucl Med 1987; 12: 581-584.
24. Jeghers O, Piepsz A, Ham HR. What does protein binding of radiopharmaceuticals mean exactly? Eur J Nucl Med 1990; 17: 101-102.
25. Fleming JS, Wilkinson J, Oliver RM, et al. Comparison of radionuclide estimation of glomerular filtration rate using technetium-99m diethylenetriaminepentaacetic acid and chromium-51 ethylenediaminetetraacetic acid. Eur J Nucl Med 1991; 18: 391-395.
26. 51Cr-EDTA overestimate true renal clearance by 10 per cent. Eur J Nucl Med 2003; 30: 4-8.
27. Freitas RS, Gutfilen B, da Fonseca LMB, Bernardo-Filho M. Evaluation of 99mtechnetium-radiopharmaceutical binding to blood elements using different trichloroacetic acid concentrations. Yale J Biol Med 1996; 69: 483-488.
28. m-DTPA compared with other GFR tracers. Nucl Med Commun 2001; 22: 617-623.
29. Vanlic-Razumenic N, Joksimovic J, Ristic B, et al. Interaction of 99mTc-radiopharmaceuticals with transport proteins in human blood. Nucl Med Biol 1993; 20: 363-365.
30. 99mTc-MDP. Nucl Med Commun 2002; 23: 405 (abstract).